01.11.2022

CO.DON AG: 5-year results of phase III clinical trial published

26.07.2022

CO.DON AG: Application for opening of insolvency proceedings

press release

05.05.2022

CO.DON AG: European Commission grants indefinite renewal of EU-wide marketing authorization for the pharmaceutical product Spherox

press release

29.04.2022

CO.DON AG: Chairman of the Supervisory Board resigns for health reasons

press release

28.03.2022

CO.DON AG: Spherox included on the list of pharmaceutical products reimbursed in Belgium

press release

21.03.2022

CO.DON AG: CO.DON AG and JOINT OPERATIONS (UK) LLP sign contract for the distribution of Spherox in United Kingdom

press release

01.03.2022

CO.DON AG: Recommendation to make EU marketing authorisation for Spherox valid for an unlimited period

press release

25.02.2022

CO.DON AG: Member of the Management Board resigns as of February 28, 2022

press release

27.01.2022

CO.DON AG (ISIN: DE 000A3E5C08 / DE000A3E5C16): Preliminary Business Figures 2021

ad hoc announcement

25.01.2022

CO.DON AG: 5-year results confirm safety and effectiveness of matrix-associated autologous chondrocyte transplantation with spheroids

press release